Biogen to acquire Apellis for $5.6 billion in cash deal
Tweet Send to a Friend
Biogen Inc. (NASDAQ: BIIB) announced it will acquire Apellis Pharmaceuticals Inc. (NASDAQ: APLS) for $41 per share in cash, representing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
